# Nektar Therapeutics

Nektar Therapeutics is an Asset Manager based in San Francisco, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Founded:** 1990
- **Assets under management:** Undisclosed
- **Website:** nektar.com
- **LinkedIn:** https://www.linkedin.com/company/nektar-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

Nektar Therapeutics is a biopharmaceutical company founded in 1990 in San Francisco, California. It focuses on developing medicines through a chemistry platform for drug discovery and design. The company's pipeline includes investigational drugs for cancer, auto-immune diseases, and viral diseases.

## Sectors

- Biotech
- Immuno-Oncology
- Immunology

## Offices

- Huntsville, AL, United States

## People

- Howard Robin — President & Chief Executive Officer
- John Northcott — Chief Commercial Officer
- Jonathan Zalevsky — Chief Research & Development Officer

## Questions

### What happened with Nektar's lead oncology program with Bristol Myers Squibb?

The Phase 3 PIVOT IO-001 trial evaluating bempegaldesleukin in combination with Opdivo in untreated metastatic melanoma failed to meet its primary endpoints for progression-free survival and overall survival in 2022. Bristol Myers Squibb terminated the global clinical collaboration shortly after. The failure led to a major restructuring at Nektar, including a 70% workforce reduction in San Francisco.

### Who are Nektar's largest pharmaceutical partners?

Eli Lilly is Nektar's most significant current partner, holding global rights to rezpegaldesleukin (NKTR-358) for autoimmune indications. Pfizer previously licensed Nektar's anti-infectives portfolio and held a royalty position on Exubera, while Bristol Myers Squibb was the oncology partner on bempeg until the collaboration ended in 2022.

### How does the polymer-conjugation platform actually work?

Nektar's technology attaches polyethylene glycol (PEG) polymers to therapeutic proteins to improve their pharmacokinetic profile — extending half-life and altering biodistribution. The platform was originally validated with PEGylated drugs like Neulasta (on-body injector) and later evolved into cytokine conjugates designed to bias immune signaling toward effector T-cells rather than regulatory T-cells.

### What is Nektar's current financial runway?

Following the 2022 workforce reductions and an operational consolidation, the company disclosed roughly $350 million in cash and marketable securities as of mid-2023. Management has guided that this provides runway into 2026, concentrated on advancing the autoimmune-focused pipeline rather than re-initiating large oncology registration trials.

### Does Nektar own its manufacturing, or is it outsourced?

Nektar owns and operates a dedicated sterile-injectable manufacturing facility in Huntsville, Alabama, which handles the complex polymer conjugation and fill-finish for its clinical pipeline. This is a genuine differentiator from most mid-cap biotechs that rely entirely on CMOs for supply.

### How is the autoimmune pivot distinct from the prior oncology strategy?

The lead autoimmune candidate, rezpegaldesleukin (partnered with Lilly), targets the IL-2 receptor to boost regulatory T-cells for immune suppression rather than stimulating killer T-cells as the oncology programs attempted. It is currently in Phase 2b for atopic dermatitis with additional studies planned in other autoimmune indications. The oncology pipeline has been substantially deprioritized.

### What is Nektar's historical relationship with Pfizer?

Pfizer acquired Nektar's pulmonary anti-infectives platform in 2006 and later took on the inhaled-insulin product Exubera, paying Nektar royalties for years. That royalty stream historically provided a material non-dilutive cash flow to fund early oncology development, although it has since expired following patent cliffs.

## Related profiles

- [Minerals Technologies](https://altss.com/profile/minerals-technologies-inc)
- [Douglas Emmett](https://altss.com/profile/douglas-emmett-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nektar-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology